AcouSort expands its cell therapy efforts and enters collaboration with global life science company
The initial aim of the collaboration is to demonstrate how AcouSort’s AcouWash technology can be adapted for industrial use and integrated as OEM components in the partnering company’s future cell therapy products and instruments. This initial collaboration project generates revenues of EUR 150,000 to AcouSort in 2022. The industry collaboration follows a two-year period where AcouSort has been involved in academic projects with similar ambitions developing cell therapy solutions for clinical use.
“Cell therapy is alongside of clinical diagnostics one of AcouSort’s focus areas. We have previously successfully collaborated with leading academic partners, and the industry collaboration we now have entered marks the beginning of the next step in our efforts to develop an attractive and scalable cell therapy platform for clinical use. It is all very exciting.”, says AcouSort’s CEO Torsten Freltoft.
This information is such information that AcouSort AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on November 14, 2022, at 8:30 CET.
